Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis

American Journal of Gastroenterology

Volumn 103, Issue 12, 2008, Pages 3106-3114

  Cortot, Antoine ^a   Maetz, Denis ^b   Degoutte, Eric ^b   Delette, Olivier ^b   Meunier, Pierre ^b   Tan, Gie ^b   Cazals, Jean Brice ^b   Dewit, Olivier ^b   Hebuterne, Xavier ^b   Beorchia, Sylvain ^b   Grunberg, Bernard ^b   Leprince, Eric ^b   D'Haens, Geert ^b   Forestier, Sylvie ^b   Idier, Isabelle ^b   Lémann, Marc ^c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Hopital Saint Louis ^*

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; ENEMA; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; FOAM; GASTROINTESTINAL SYMPTOM; HUMAN; INTERMETHOD COMPARISON; LIQUID; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROCTITIS; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; REMISSION; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TREATMENT DURATION; ULCERATIVE COLITIS; ADOLESCENT; AGED; DRUG DOSAGE FORM; METHODOLOGY; MIDDLE AGED; PROCTOCOLITIS; RECTAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, RECTAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOSAGE FORMS; ENEMA; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PROCTITIS; PROCTOCOLITIS; SINGLE-BLIND METHOD; TREATMENT OUTCOME; YOUNG ADULT;

EID: 58149401224     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2008.02152.x     Document Type: Article

References (29)

1. Campieri M, Paoluzzi P, D'Albasio G, et al. Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis. Dig Dis Sci 1993 38 : 1843 50.
2. Campieri M, Gionchetti P, Belluzzi A, et al. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 1991 32 : 929 31.
3. Campieri M, Lanfranchi GA, Bazzocchi G, et al. Treatment of ulcerative colitis with high dose 5-aminosalicylic acid enema. Lancet 1981 2 : 270 1.
4. Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: A meta-analysis. Aliment Pharmacol Ther 1995 9 : 293 300.
5. Hanauer SB. Dose ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: Results of a multicentered placebo-controlled trial. The US PENTASA Enema Study Group. Inflamm Bowel Dis 1998 4 : 79 83.
6. Pullan RD, Ganesh S, Mani V, et al. Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: A controlled trial. Gut 1993 34 : 676 9.
7. Lee FI, Jewell DP, Mani V, et al. A randomised trial comparing mesalazine and prednisolone foam enemas in patients with active distal ulcerative colitis. Gut 1996 38 : 229 33.
8. Cohen RD, Voseth DM, Thisted RA, et al. A meta-analysis and over view of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000 95 : 1263 76.
9. Campieri M, Corbelli C, Gionchetti C, et al. Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. Dig Dis Sci 1992 37 : 1890 7.
10. Gionchetti P, Ardizzone S, Benvenuti ME, et al. A new mesalazine gel enema in the treatment of left sided ulcerative colitis: A randomized controlled multicentre trial. Aliment Pharmacol Ther 1999 13 : 381 8.
11. Ardizzone S, Doldo P, Ranzi T, et al. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparison trial vs Salofalk enema. The SAF-3 study group. Ital J Gastroenterol Hepatol 1999 31 : 677 84.
12. Malchow H, Gertz B, and the Clafoam Study Group. A new mesalazine foam enema (Claversal foam) compared with a standard liquid enema in patients with active distal ulcerative colitis. Aliment Pharmacol Ther 2002 16 : 415 23.
13. Pokrotnieks J, Marlicz K, Paradowski L, et al. Efficacy and tolerability of mesalazine foam (Salofalk foam) for distal ulcerative colitis: A double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther 2000 14 : 1191 8.
14. Eliakim R, Tulassay Z, Kupcinskas L, et al. Clinical trial: Randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis. Aliment Pharmacol Ther 2007 26 : 1237 49.
15. Clinical Study Report PPL 469 (Sept 2002). Ferring Pharmaceuticals, Mesalazine foam: Internal data. Unpublished results.
16. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomized trial. BMJ 1989 289 : 82 6.
17. European Medicines Agency. Evaluation of medicines for human use. London, 27 July 2005. Doc. Ref. EMEA/CPMP/EWP/482/99. Available at : http://www.emea.europa.eu/pdfs/human/ewp/048299en.pdf.
18. ICH Topic E9. Statistical principles for clinical trials. September 1998. Available at : http://www.fda.gov/cder/guidance/index.htm.
19. Sutherland LR, Martin F, Greer S, et al. 5-amicosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiiditis, and proctitis. Gastroenterology 1987 92 : 1894 8.
20. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: A meta-analysis. Gut 1997 40 : 775 81.
21. Gionchetti P, Venturi A, Rizello F, et al. Retrograde colonic spread of a new mesalazine rectal enema in patients with distal ulcerative colitis. Aliment Pharmacol Ther 1997 11 : 679 84.
22. Sandborn WJ, Stenson WJ, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: A randomized, placebo-controlled pilot study. Clinical Gastroenterol Hepatol 2006 4 : 203 11.
23. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004 53 : 1617 23.
24. Lemann M, Mary JY, Colombel JF, et al. A randomized, double blinded, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005 128 : 1812 8.
25. Tinmouth JM, Steele LS, Tomlinson G, Glazier RH. Are claims of equivalence in digestive trials supported by evidence? Gastroenterology 2004 126 : 1700 10.
26. European Medicines Agency. Pre-authorisation evaluation of medicines for human use. London, 27 July 2005. Doc. Ref. EMEA/CPMP/EWP/2158/99. Available at : http://www.emea.europa.eu/pdfs/human/ewp/215899en.pdf.
27. Raedler A, Bherens C, Biast P. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis. Results from a randomized-controlled trial. Aliment Pharmacol Ther 2004 20 : 1353 63.
28. Gross V, Bar-Meir S, Lavy A, et al. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther 2006 23 : 303 12.
29. Gibson PR, Fixat B, Pekarkova B, et al. Comparison of the efficacy and safety of Eudragit-L-cated mesalazine tablets with ethycellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Aliment Pharmacol Ther 2006 23 : 1017 26.